Home » Stocks » Aoxing Pharmaceutical

Aoxing Pharmaceutical Company, Inc. (AOXG)

Stock Price: $0.0100 USD -0.0017 (-14.53%)
Updated Aug 10, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 762,090
Revenue (ttm) 30.11M
Net Income (ttm) -1.46M
Shares Out 76.21M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $0.0100
Previous Close $0.0117
Change ($) -0.0017
Change (%) -14.53%
Day's Open 0.0090
Day's Range 0.0090 - 0.0090
Day's Volume 225
52-Week Range 0.0056 - 0.0290

More Stats

Market Cap 762,090
Enterprise Value 20.62M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 76.21M
Float 46.19M
EPS (basic) -0.02
EPS (diluted) -0.02
FCF / Share -0.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 13,236
Short Ratio 0.03
Short % of Float 0.03%
Beta 3.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.03
PB Ratio 0.07
Revenue 30.11M
Operating Income 967,218
Net Income -1.46M
Free Cash Flow -1.39M
Net Cash -19.86M
Net Cash / Share -0.26
Gross Margin 81.56%
Operating Margin 3.21%
Profit Margin -4.90%
FCF Margin -4.63%
ROA 1.00%
ROE -7.56%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $0.0100
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2016201520142013201220112010200920082007
Revenue32.3325.4812.7410.838.136.656.128.947.071.94
Revenue Growth26.88%100.02%17.63%33.14%22.3%8.75%-31.61%26.57%264.43%-
Gross Profit24.5519.795.816.274.903.323.773.813.230.90
Operating Income6.238.70-3.33-14.22-14.55-4.86-3.58-6.35-3.58-1.41
Net Income2.065.49-8.22-16.80-15.82-7.41-0.83-2.453.65-14.77
Shares Outstanding73.7063.1149.8649.7549.3546.5845.5841.2024.6220.05
Earnings Per Share0.030.09-0.16-0.34-0.32-0.16-0.02-0.060.16-0.70
EPS Growth-66.67%---------
Operating Cash Flow-0.533.03-7.73-8.32-1.33-2.67-3.98-0.64-0.98-14.21
Capital Expenditures-0.12-2.71-0.27-0.44-0.75-1.37-2.00-2.23-1.48-1.11
Free Cash Flow-0.650.32-8.00-8.76-2.08-4.05-5.97-2.87-2.46-15.32
Cash & Equivalents7.685.372.334.013.682.773.991.271.571.51
Total Debt25.4730.4532.0425.5615.6612.4714.8417.9115.2814.17
Net Cash / Debt-17.79-25.07-29.71-21.55-11.98-9.70-10.86-16.64-13.71-12.66
Assets56.2353.0438.0739.7345.0955.8758.3356.7456.1321.18
Liabilities38.1642.9843.7435.1523.8220.1624.0232.1130.9930.72
Book Value19.1411.24-2.515.6721.8836.3134.5724.8925.14-10.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aoxing Pharmaceutical Company, Inc.
Country United States
Employees 346
CEO Zhen Jiang Yue

Stock Information

Ticker Symbol AOXG
Stock Exchange US OTC
Unique Identifier OTCMKTS: AOXG

Description

Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.